IN THE SPOTLIGHT

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1

Impact of eGFR estimation methods on drug dosing in pediatric ICU: a study of serum creatinine vs. cystatin C

Impact of eGFR estimation methods on drug dosing in pediatric ICU: a study of serum creatinine vs. cystatin C

ARTS Trial: Adjuvant Aumolertinib in Resected EGFR-Mutated NSCLC

ARTS Trial: Adjuvant Aumolertinib in Resected EGFR-Mutated NSCLC

Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells

Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells

FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells

FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells

New activities of homoyessotoxin against lung cancer through the regulation of EGFR/PI3K/AKT pathway

New activities of homoyessotoxin against lung cancer through the regulation of EGFR/PI3K/AKT pathway